Am J Cardiol. 1997 May 1;79(9):1248-52.
A placebo-controlled, double-blind study on the efficacy of atorvastatin was conducted in several multicenters. Atorvastatin reduced total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B substantially in a dose-dependent manner without any serious adverse events.
在多个中心进行了一项关于阿托伐他汀疗效的安慰剂对照双盲研究。阿托伐他汀以剂量依赖方式显著降低总胆固醇、低密度脂蛋白胆固醇和载脂蛋白B,且无任何严重不良事件。